<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02009826</url>
  </required_header>
  <id_info>
    <org_study_id>CAPRI13/37/348</org_study_id>
    <secondary_id>B300201318710</secondary_id>
    <nct_id>NCT02009826</nct_id>
  </id_info>
  <brief_title>Psychosis-Associated Neuroinflammation in Schizophrenia</brief_title>
  <acronym>PANS</acronym>
  <official_title>Phase 0 Clinical Protocol: A Longitudinal and Multimodal Exploratory Study to Evaluate a Neuroinflammatory Hypothesis in Patients With Schizophrenia Compared to Young Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Universiteit Antwerpen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Agentschap voor Innovatie door Wetenschap en Technologie</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Janssen Research &amp; Development, LLC</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Universiteit Antwerpen</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Previous research has suggested central nervous system inflammatory activity to be critically&#xD;
      involved in disease development and progression in schizophrenia, with a complex interplay of&#xD;
      inflammatory mechanisms leading to the development of brain abnormalities and medical&#xD;
      symptoms related to schizophrenia. However, the mutual interactions of different inflammatory&#xD;
      pathways and their relation to disease course have not been sufficiently studied. This study&#xD;
      therefore aims to explore the interaction of neuroinflammatory mechanisms in patients with&#xD;
      schizophrenia and to assess whether the inflammatory activity in schizophrenia is&#xD;
      state-dependent and occurs mainly during psychotic episodes.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2013</start_date>
  <completion_date type="Actual">February 2017</completion_date>
  <primary_completion_date type="Actual">February 2017</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Regional VT of [18F]PBR111</measure>
    <time_frame>2 years</time_frame>
    <description>Regional distribution volume in tissue (VT) of 2-(6-chloro-2-(4-(3-fluoropropoxy)phenyl)imidazo(1,2-a)pyridin-3-yl)-N,N-diethylacetamide (PBR111) labelled with fluorine-18 (18F) in schizophrenia patients and age- , gender-, and translocator protein (TSPO) binding profile- matched healthy controls</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Peripheral markers</measure>
    <time_frame>2 years</time_frame>
    <description>Levels and ratios of inflammatory and neurotoxicity markers in blood samples of schizophrenia patients compared to healthy age- and gender-matched healthy controls.</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">106</enrollment>
  <condition>Schizophrenia</condition>
  <condition>Psychosis</condition>
  <arm_group>
    <arm_group_label>Healthy controls</arm_group_label>
    <description>Healthy age- and sex-matched controls</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Schizophrenia patients</arm_group_label>
    <description>Young schizophrenia patients 18-40y</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>[18F]-PBR111 Positron Emission Tomography (PET)</intervention_name>
    <description>[18F]-PBR111 radioligand to assess binding to TSPO</description>
    <arm_group_label>Healthy controls</arm_group_label>
    <arm_group_label>Schizophrenia patients</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Cognitive and psychomotor tasks</intervention_name>
    <description>Cognitive and psychomotor tasks on digitizing tablet</description>
    <arm_group_label>Healthy controls</arm_group_label>
    <arm_group_label>Schizophrenia patients</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Blood sampling</intervention_name>
    <description>Blood sampling for peripheral inflammatory and neurotoxicity markers</description>
    <arm_group_label>Healthy controls</arm_group_label>
    <arm_group_label>Schizophrenia patients</arm_group_label>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Plasma samples&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Young schizophrenia patients admitted to psychiatric hospital for acute relapse or&#xD;
        first-episode of psychosis&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Be a man or woman between 18 and 40 years of age, inclusive.&#xD;
&#xD;
          -  Have signed an informed consent document indicating that they understand the purpose&#xD;
             of and procedures required for the study and are willing to participate in this study.&#xD;
&#xD;
          -  Be medically stable on the basis of physical examination and vital signs performed at&#xD;
             Screening.&#xD;
&#xD;
          -  Be medically stable on the basis of clinical laboratory tests performed at Screening.&#xD;
             If the results of the serum chemistry panel, hematology, or urinalysis are outside the&#xD;
             normal reference ranges, the subject may be included only if the investigator judges&#xD;
             the abnormalities or deviations from normal to be not clinically significant or to be&#xD;
             appropriate and reasonable for the population under study.&#xD;
&#xD;
          -  Be willing and able to adhere to the prohibitions and restrictions specified in the&#xD;
             protocol.&#xD;
&#xD;
        Schizophrenia subjects:&#xD;
&#xD;
          -  Fulfill DSM-V criteria for the schizophrenia spectrum (DSM-V #295.1-295.6, 295.9,&#xD;
             298.9)&#xD;
&#xD;
          -  Be admitted to hospital for first-episode psychosis or acute relapse of psychosis, as&#xD;
             defined by:&#xD;
&#xD;
        total score of ≥14 on the positive scale of the &quot;Positive and Negative Syndrome Scale&quot;&#xD;
        (PANSS) and at least a score of 5 on 1 item or a score of 4 on 2 &quot;psychotic&quot; PANSS items&#xD;
        P2, P3, P5 or G9 at Screening.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Use of nonsteroidal antiinflammatory drugs, paracetamol, immunosuppressant or&#xD;
             immunostimulating drugs within 21 days of screening.&#xD;
&#xD;
          -  Use of systemic corticosteroids within 21 days of screening.&#xD;
&#xD;
          -  Has a history of drug or alcohol dependence according to DSM-V criteria, except&#xD;
             nicotine or caffeine, within 6 months before screening.&#xD;
&#xD;
          -  Has history of (co-morbid) somatization or mood disorder according to DSM-V criteria&#xD;
             within 6 months before screening.&#xD;
&#xD;
          -  Has a positive test result for drugs of abuse or for alcohol at screening or test day.&#xD;
&#xD;
          -  Female subjects only: is pregnant or breastfeeding&#xD;
&#xD;
          -  Has a history of chronic or acute physical illness associated with abnormal immune&#xD;
             changes within the 2 weeks before the study.&#xD;
&#xD;
          -  Leukocytosis (i.e., white blood cell count ≤ 11 x109 /L) on screening and test days.&#xD;
&#xD;
          -  Serology positive for hepatitis B surface antigen (HBsAg), hepatitis C antibodies, or&#xD;
             HIV antibodies at screening.&#xD;
&#xD;
          -  Has a medical history of any auto-immune disorder or chronic inflammatory disease.&#xD;
&#xD;
          -  Has received electroconvulsive therapy in the last 6 months.&#xD;
&#xD;
          -  Is currently enrolled in a study with an investigational study drug.&#xD;
&#xD;
          -  Worsening or first time occurrence of significant suicidality&#xD;
&#xD;
          -  Has donated blood within 3 months before screening.&#xD;
&#xD;
          -  Has any condition that, in the opinion of the investigator, would compromise the&#xD;
             wellbeing of the subject or the study or prevent the subject from meeting or&#xD;
             performing study requirements.&#xD;
&#xD;
          -  Low affinity binder of the TSPO, as determined by rs6971 polymorphism genotyping at&#xD;
             Screening&#xD;
&#xD;
          -  Use of benzodiazepines for 3x the half-life prior to PET-scan&#xD;
&#xD;
          -  Presence of irremovable magnetic materials in or on the body&#xD;
&#xD;
          -  Has a medical history of organic brain disease&#xD;
&#xD;
          -  Has a medical history of traumatic brain injury&#xD;
&#xD;
          -  Has a medical history of allergic reaction to any of the substances in the tracer&#xD;
             fluid.&#xD;
&#xD;
          -  Unwillingness or inability of subject to undergo PET and/or MRI scan (for example due&#xD;
             to claustrophobia or lack of cooperation)&#xD;
&#xD;
        Healthy volunteers:&#xD;
&#xD;
          -  Personal history of psychotic disorder&#xD;
&#xD;
          -  Family history of psychotic or bipolar disorder in first-degree relatives&#xD;
&#xD;
          -  Family history of auto-immune disorder in first-degree relatives&#xD;
&#xD;
        Schizophrenia patients:&#xD;
&#xD;
        - Calgary Depression Scale for Schizophrenia (CDSS) score &gt;6 at screening&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bernard Sabbe, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Universiteit Antwerpen</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Psychiatrisch Ziekenhuis Broeders Alexianen</name>
      <address>
        <city>Boechout</city>
        <state>Antwerpen</state>
        <zip>2530</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Psychiatrisch Ziekenhuis St Norbertus</name>
      <address>
        <city>Duffel</city>
        <state>Antwerpen</state>
        <zip>2570</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Psychiatrisch Ziekenhuis Sint-Amedeus</name>
      <address>
        <city>Mortsel</city>
        <state>Antwerp</state>
        <zip>2640</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>August 2017</verification_date>
  <study_first_submitted>December 9, 2013</study_first_submitted>
  <study_first_submitted_qc>December 9, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 12, 2013</study_first_posted>
  <last_update_submitted>August 30, 2017</last_update_submitted>
  <last_update_submitted_qc>August 30, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 31, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Universiteit Antwerpen</investigator_affiliation>
    <investigator_full_name>Dr Livia De Picker</investigator_full_name>
    <investigator_title>Medical Doctor</investigator_title>
  </responsible_party>
  <keyword>Schizophrenia</keyword>
  <keyword>Psychosis</keyword>
  <keyword>Neuroinflammation</keyword>
  <keyword>Microglial activation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Schizophrenia</mesh_term>
    <mesh_term>Psychotic Disorders</mesh_term>
    <mesh_term>Mental Disorders</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

